Drug intelligence / Profile preview

MNKD-701

Development stage: Preclinical
Lead developer: Mannkind
Modality: Small Molecules
Administration: Inhalation

Overview

MNKD-701 is an investigational dry powder inhaler (DPI) formulation of bumetanide, a potent loop diuretic, being developed by MannKind Corporation. The drug is designed for the treatment of fluid overload (edema) associated with conditions such as heart failure and chronic kidney disease. By utilizing MannKind's proprietary dry powder technology, MNKD-701 aims to provide a rapid-onset, non-invasive delivery route compared to traditional oral or intravenous administration. As of early 2026, the program is in pre-clinical development, leveraging the company's expertise in inhaled drug-device combinations for cardiometabolic and orphan lung diseases.

Other names: Bumetanide DPIInhaled bumetanide

Targets

NKCC2 (Sodium-potassium-chloride cotransporter 2)

Beyond the preview

Go deeper on MNKD-701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MNKD-701.

Explore the full profile